Single-arm, phase II trial: overall survival and biomarker analysis of neoadjuvant Nivolumab plus chemotherapy in operable stage IIIA non–small-cell lung cancer.
30 May, 2022 | 10:39h | UTC
Commentary on Twitter
In NADIM study of neoadj chemo + nivo for stage IIIA NSCLC, 3-y OS was 91%; low levels of pretreatment ctDNA and undetectable ctDNA after neoadjuvant therapy were predictive of OS (with HRs of 0.07 and 0.04, respectively) https://t.co/BIprSnDICd
— NatureRevClinOncol (@NatRevClinOncol) May 18, 2022